NCT05628961View on ClinicalTrials.gov

Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Toxicity;Chemical
Interventions
DRUG

HOPO 14-1

HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.

Trial Locations (1)

48170

RECRUITING

SRI Biosciences Clinical Trials Unit, Plymouth

Sponsors

Lead Sponsor

SRI International
All Listed Sponsors
lead

SRI International

INDUSTRY

NCT05628961 - Study of Single Oral Doses of HOPO 14-1 Evaluating Safety, Tolerability, Pharmacokinetics | Biotech Hunter | Biotech Hunter